Ensysce Biosciences reported a significant net loss of $88.2 million for the nine months ended September 30, 2026, primarily driven by a $79.9 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity position, ending the period with $29.7 million in cash following multiple preferred stock and PIPE financing transactions.
Ensysce Biosciences reported financial results for the third quarter of 2026, highlighting the completion of its acquisition of Cy Biopharma and the addition of lead asset CY200 for Complex Regional Pain Syndrome. The company ended the quarter with a strengthened cash position of $29.7 million and submitted a Phase 2a protocol for CY200 to the UK's MHRA.
Term
Q3 2026
“Ensysce is a fundamentally different company today than it was at the start of the year. With CY200, we now lead with a potentially first-in-class approach to CRPS, a devastating condition for which there is currently no FDA-approved therapy.”
Dr. Lynn Kirkpatrick, Chief Executive Officer
“Our priority since the acquisition has been to advance CY200 efficiently, and submitting the CYBIO 001 protocol to the MHRA in September was a significant first step.”
Ensysce Biosciences announced a leadership transition where current CEO Dr. Lynn Kirkpatrick will step down and assume the role of Chief Operating Officer following the annual meeting on December 14, 2026. Current President James Morrisson will succeed her as Chief Executive Officer. Additionally, board member Will Chang notified the company of his intention to resign following the same annual meeting.